By SPC News Staff
The FDA approved tafamidis meglumine (Vyndaqel, Pfizer) and tafamidis (Vyndamax, Pfizer) capsules to treat cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR-CM) in adults.
Vyndaqel and Vyndamax are two oral formulations of the first-in-class transthyretin stabilizer tafamidis, and the only medicines indicated for ATTR-CM. Although they have the same active moiety, tafamidis, they are not substitutable on a milligram-to-milligram basis and their recommended